❌

Normal view

There are new articles available, click to refresh the page.
Before yesterdayMain stream

A browser is born

✇MetaFilter
By: kliuless
2 July 2024 at 02:10
Ladybird: A new cross-platform browser project - "The Ladybird browser came to life on July 4th [2022]"* and now today Announcing the Ladybird Browser Initiative via Simon Willison: "Andreas Kling's Ladybird is a really exciting project: a from-scratch implementation of a web browser, initially built as part of the Serenity OS project, which aims to provide a completely independent, open source and fully standards compliant browser." (previously)

What is language attrition?

✇MetaFilter
By: bq
25 June 2024 at 12:38
"When I moved to the Netherlands a long time ago (I was 33 years old at the time), I was determined to learn Dutch quickly. I did not, of course, expect to become perfect – I knew I would occasionally fumble for words, my grammar would at times be erratic, and many (if not most) conversations with strangers would quickly lead up to the inevitable question "Where do you come from?" This, after all, is what usually happens when you learn a new language later in life – and tons and tons of research are there to support this. What I did not expect was for the same things to happen to my native German." This website created by Dr. Monika S. Schmid, Professor of Linguistics, University of York, shares information about the science of language attrition, what it looks like for adults, children, and other groups, anecdotes, media coverage, celebrity examples, and research tools.

Drugmaker to testify on why weight-loss drugs cost 15x more in the US

✇Ars Technica
By: Beth Mole
17 June 2024 at 15:14
Lars Fruergaard Jorgensen, chief executive officer Novo Nordisk A/S, during an interview at the company's headquarters in Bagsvaerd, Denmark, on Monday, June 12, 2023.

Enlarge / Lars Fruergaard Jorgensen, chief executive officer Novo Nordisk A/S, during an interview at the company's headquarters in Bagsvaerd, Denmark, on Monday, June 12, 2023. (credit: Getty | Carsten Snejbjerg)

After some persuasion from Sen. Bernie Sanders (I-Vt.), the CEO of Novo Nordisk will testify before lawmakers later this year on the "outrageously high cost" of the company's diabetes and weight-loss drugs—Ozempic and Wegovy—in the US.

CEO Lars Jørgensen will appear before the Senate Committee on Health, Education, Labor, and Pensions (HELP), which is chaired by Sanders, in early September. The agreement came after a conversation with Sanders in which the CEO reportedly "reconsidered his position" and agreed to testify voluntarily. As such, Sanders has canceled a vote scheduled for June 18 on whether to subpoena Novo Nordisk to discuss its US prices, which are considerably higher than those of other countries.

The independent lawmaker has been working for months to pressure Novo Nordisk into lowering its prices and appearing before the committee. In April, Sanders sent Jørgensen a letter announcing an investigation into the prices and included a lengthy set of information requests. In May, the committee's investigation released a report suggesting that Novo Nordisk's current pricing threatens to "bankrupt our entire health care system."

Read 6 remaining paragraphs | Comments

❌
❌